Randox Cardiology Reagents Panel
Randox is a leading provider of diagnostic reagents for the assessment of cardiovascular disease risk. Our extensive menu of cardiac biomarkers within the cardiology reagents panel include:
Routine lipid tests such as Homocysteine, hsCRP, Apo A-I, Apo A-II, Apo B and Lp(a). Our cardiology reagents offer superior performance and are available for use on a wide range of clinical chemistry analysers.
Unique assays for cardiac risk assessment include sdLDL Cholesterol, Apo C-II, Apo C-III, Apo E and Adiponectin. In addition, our range of unique cardiology reagents includes H-FABP for the early detection of myocardial infarction.
Benefits of Randox Cardiology Assays
- Liquid ready-to-use reagents for convenience; we also offer lyophilised reagents for CK-MB, HDL Cholesterol and Triglycerides
- Wide measuring ranges for accurate detection of abnormal levels
- Strong correlation to reference methods for trusted results
- Applications available for a wide range of clinical chemistry analysers
- Unique reagents enable impeccable patient care with an expanded profile for cardiac risk assessment
CRP (HIGH SENSITIVITY)
HEART-TYPE FATTY ACID BINDING PROTEIN (H-FABP)
Cardiovascular disease refers to a variety of diseases which cause reduced blood flow to the heart, brain or body and is alos a leading cause of death. Such diseases include those affecting the blood vessels supplying the heart (coronary heart disease), brain (cerebrovascular disease), and arms and legs (peripheral arterial disease). Restrictions to blood flow can be a result of a blood clot (thrombosis), or narrowed arteries caused by a build-up of fatty deposits (atherosclerosis). The effects of this can lead to stroke or heart attack.
- H-FABP (Heart-type fatty acid binding protein) test is a rapid, accurate and a highly sensitive early rise marker of acute coronary syndrome. It is a novel marker which offers quick detection; it is detectable as early as 30 minutes following the onset of an Ischemic episode providing rapid diagnosis when it is critically needed.
- CK-MB useful in patients with chest pain; Creatine Kinase is an enzyme produced in many different types of cells, of which high levels indicate muscle trauma or damage.
- Myoglobin, a small protein which leaks out of muscle cells after injury, is also considered a biomarker for the detection of Myocardinal Infraction.
- Routine lipid tests to determine the patient’s cholesterol and triglyceride levels – HDL Cholesterol, LDL Cholesterol, Total Cholesterol and Triglycerides
- Independent risk assessment tests such as sdLDL Cholesterol and Lipoprotein(a) to determine any genetic factors which may increase their risk of CVD. Please note, this is necessary even for patients who have good cholesterol levels
- Secondary tests, such as hsCRP, in addition to risk assessment markers and lipid evaluation – secondary tests are important in predicting future cardiac events of individuals with no previous history of CVD and those deemed healthy as a result of primary tests; approximately half of all heart attacks occur in patients classified as low risk. In addition, they can also be used to evaluate the risk of a recurrent cardiac event
- Speciality tests include
- Homocysteine – elevated levels of homocysteine have been linked to various disease states including CVD. Extremely high levels are found in patients with homocystinuria, of which many suffer from early arteriosclerosis
- Adiponectin – low levels of Adiponectin indicate high abdominal visceral fat, which can increase a patient’s cardiovascular risk. It provides a much clearer indication of health than BMI scoring which does not indicate the patient’s level of body fat.